Cannabis growers, traders, license holders, physicians, patients, regulatory authorities, capital investors, professionals, and enthusiasts are invited to attend the CannaCon Cleveland Conference at the Huntington Convention Center, Cleveland, on October 3-4, 2024. The venue of the event, the Huntington Convention Center is situated in the heart of downtown Cleveland, near the legendary Rock & Roll Hall of Fame and the International Women’s Air & Space Museum, among others.

The CannaCon event offers a robust platform for the local cannabis community, with two full days of innovation, learning, networking, and collaboration. Exhibitors from around the world will be pitching their latest products and services to a crowd of established investors and business experts in the cannabis industry. Newbies and startups gain important visibility by showcasing their unique products and services for the right target audience.

Local businesses will be there to connect with cannabis leaders and investors. Attendees will witness an impressive lineup of industry leaders presiding as guest speakers. They will share invaluable insights about current industry trends and discuss the critical issues of current cannabis trade.

These leaders will cover a number of engaging topics, offering the best path forward to the cannabis community. From harvest quality to understanding the best practices to comply with rules and regulations, attendees can get answers to their queries regarding cannabis cultivation and trade in Cleveland.

Several plush accommodations are available near the Huntington Convention Center for the attendees. CannaCon serves as a business as well as an educational experience. Attendees will discover a wealth of information, products, and valuable connections, from cultivation supplies, cannabis innovations, discoveries in genetics,  and a wide range of vendor retail displays, to important scientific, legal, financial, and marketing ideas. Don’t miss out on this rich event.

To learn more, please visit https://ibn.fm/zg7DP

Join the crypto saga as Crypto Fest returns with its 6th edition, bringing together the dynamic African crypto and blockchain community in the picturesque city of Cape Town, South Africa on October 10-12th, 2024. This year Crypto Fest 2024 expands over three days with the main event on the 11 October taking place at the iconic DHL Stadium, home to the FIFA World Cup in 2010 a centrally located iconic landmark with excellent facilities, accessibility, and a rich legacy.

Bitcoin Events has been the proud host of Crypto Fest for the last five years, and has witnessed thousands of attendees from 120 countries, 5 events, and 160+ speakers thus far. The event brings together executives, professionals, innovators and brands from the realms of cryptocurrency, blockchain, NFTs, the Metaverse, Web3, and Decentralized Finance (DeFi).

Crypto Fest 2024 offers a phenomenal networking platform where 500+ attendees can participate in well-equipped workshops, informative sessions, exhibitions of the latest products and technologies, and other networking events. World leaders make their presence felt at the Crypto Fest event, offering invaluable ideas and expertise for the best way ahead into the world of cryptocurrencies and blockchain technology.

On Day 1, the Crypto Fest 2024 commences with a great city tour, while allowing attendees to forge connections and cultivate meaningful relationships amidst scenic landscapes. Day 2 will feature 15+ sessions hosted by international and local speakers. These global leaders will offer insights and strategies on the latest trends and emerging technologies. On day 3, the participants can relax and unwind with a captivating Cape Town Winelands Tour.

Participants at Crypto Fest can explore and learn the intricacies of finance and technology to more effectively navigate the crypto space. Attendees can participate in numerous events, winning prizes and taking advantage of freebies, while learning how to take their experience to the next level.

To learn more, please visit https://ibn.fm/Fcs1V

Businesses, entrepreneurs, investors, educators, patients, advocates, and consumers are invited to attend the NECANN Michigan Cannabis Convention on September 20-21, 2024, in Grand Rapids. NECANN events are organized to meet the needs and provide collaborative opportunities for the local cannabis community. One of the biggest cannabis conventions in the country, NECANN events witness some of the most eminent dignitaries of the cannabis spectrum gracing the event floor.

Instead of hosting generic cannabis conventions, NECANN took a customized approach. As every region has its challenges, NECANN understands the specific requirements relevant to the area. They collaborate with local traders, growers, investors, sponsors, and industries, so that the regional cannabis community benefits as a whole and enjoys a higher ROI. Operational since 2014, the NECANN team ensures all industry leaders and companies attend the event, expanding business opportunities for local cannabis traders.

Investors can discover fresh and innovative talent at the event. Budding companies can showcase their products and services at the exhibition booths. Investors and cannabis traders can have one-on-one conversations and develop business ties. Attendees can gain insights into the latest trends, and get know-how on the latest industry products and services at the NECANN event.

Top industry leaders conduct speaker sessions where they will share their invaluable expertise. Attendees can gain immense knowledge about current cannabis markets, and can learn about the tips, resources, and tools required to design winning marketing strategies in a competitive cannabis landscape. Experts presiding over the discussion panels will discuss new trends and techniques for the cannabis market to help businesses drive higher ROI.

To know more, please visit https://ibn.fm/JlL43

• Survey indicates sizable proportion of older adult population copes with healthcare costs by skipping treatments, cutting back on basic and essential needs
• Astiva Health is keenly aware of problems faced by underserved senior population
• The company strives to bridge healthcare gaps through proactive, culturally responsive solutions

As growing numbers of the U.S. population reach age 65, the challenge of adequate healthcare becomes even more critical. In fact, a West Health-Gallup survey reports that some elderly are forgoing needed care because of healthcare costs (https://ibn.fm/pJGqA). Astiva Health, a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan, is on a mission to meet the challenges faced by underserved aging populations by reshaping the landscape of personalized and comprehensive healthcare.

“The West Health-Gallup survey shows that a sizable proportion of the older adult population copes with healthcare costs by skipping treatments and cutting back on basic and essential needs,” the Gallup report stated. “The avoidance of vital medical care could compound negative health outcomes now and in the future.

“Twelve percent of those 65 and older — which represents approximately 6.5 million people — say they or a member of their household had a health problem in the last year that they did not seek treatment for due to cost,” the article continued. “Eleven percent of Americans in this age group — six million people — report that they or a family member skipped prescribed pills to save money.”

Astiva Health is keenly aware of the problems faced by the underserved senior population and has set out to offer solutions carefully designed to serve specific groups. Currently focused on addressing the healthcare needs of individuals across Southern California, the company serves Medicare enrollees in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino, offering full medical, drug, and supplemental benefits.

Recognizing the critical need for healthcare solutions designed to meet specific needs, Astiva Health is initially focused on serving the Asian American and Pacific Islander populations, which positions the company in a critical and expanding market segment that offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Additionally, Astiva Health focuses on supporting its senior members, many of whom are struggling with daily needs due to the rising cost of living while receiving a modest monthly income. Astiva addresses these challenges by maximizing supplemental benefits that are most practical for their members, such as grocery and transportation assistance, vision, hearing, and dental care. The company also provides benefits designed to keep seniors engaged, such as gym and sports club memberships, and out-of-country travel health insurance.

“Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials, and educational resources,” the company states. “Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.”

That concept is captured in the company’s mission, which is to deliver an unparalleled level of quality care to its members and offer Medicare Advantage plans that provide lower costs and additional benefits beyond original Medicare coverage. In fact, Astiva Health works closely with a variety of partners that offer services such as transportation, vision, dental, hearing, fitness, telehealth, acupuncture, and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Astiva Health is committed to being a leader in the Medicare Advantage space. The company will reach that objective by offering community-based health plans focused on serving individual member needs and tailored comprehensive benefit packages that best support its local, underserved member population.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs
• The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity
• Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition

According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and 79 globally have diabetes. In addition, almost half of them are unaware that they are living with the condition. The Federation further projects that by 2045, one in eight adults in the world will be living with diabetes. This will represent approximately 783 million people, an increase of 46% from the current numbers (https://ibn.fm/yow5m).

The figures in the United States are just as startling, with 38.4 million people of all ages, or 11.6% of the country’s population having diabetes, according to the Centers for Disease Control (“CDC”) (https://ibn.fm/hXwVn). Also, a Population Health Management report shows estimates that, by 2030, over 54.9 million Americans will have diabetes, representing a 54% increase between 2015 and 2030 (https://ibn.fm/GGPTB). These statistics have prompted organizations and societies to initiate and sustain conversations around diabetes and its management.

They have also pushed organizations to explore ways to manage the condition better, and one that has stood out is Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. Lexaria looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. Testing conducted since 2016, has demonstrated the technology’s ability to increase bio-absorption. It has even evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, with its range of applications scaling across bioactive molecules, oral cannabinoids, and other active pharmaceutical ingredients (“APIs”).

Lexaria has recently made strides with glucagon-like peptide-1 (“GLP-1”) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. In the last month, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss (https://ibn.fm/dJuuy).

GLP-1 drugs have been lauded for their potential to treat diabetes. However, when consumed orally, the stomach’s acidic environment seriously degrades its bioavailability, resulting in meager blood absorption rates of less than 1%, which is far from ideal. This has restricted their administration to painful injections, which can be a deterrent to some people.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/RepgJ).

With Lexaria’s DehydraTECH technology, increased bioavailability has been evidenced, bringing the company closer to offering a viable alternative to injectable delivery of GLP-1 drugs. In addition, the studies conducted so far have shown better tolerability of the GLP-1 drugs used, mainly Rybelsus(R), further pointing to the technology’s superiority and highlighting its potential in treating weight loss and diabetes.

Lexaria recognizes a market opportunity with its technology. It also recognizes a growing problem that needs to be addressed sooner rather than later. For a market valued at $79.3 billion in 2023, the company looks to create significant additional value for its shareholders (https://ibn.fm/OfKl0). As it continues with its GLP-1 studies, its management is optimistic about their outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The collaboration aims to enhance the development and deployment of integrated quantum and generative AI solutions within D-Wave’s Leap™ quantum cloud platform
• The partnership’s development efforts will target more efficient and energy-saving model training, higher-performing models, and the combined application of Generative AI and quantum optimization
• The commercial expansion includes a one-year enterprise subscription to Orquestra®, Zapata AI’s powerful software development and collaboration platform designed for creating and deploying Universal Generative AI applications at scale
• D-Wave recently hosted British Columbia (B.C.) Minister of State for Trade, Jagrup Brar, and B.C. Parliamentary Secretary for Labour, Janet Routledge, at its Burnaby-based Quantum Engineering Center of Excellence

D-Wave Quantum (NYSE: QBTS), a pioneer in quantum computing systems, software, and services, and Zapata Computing Holdings (NASDAQ: ZPTA), known for its expertise in industrial generative AI software solutions, have announced a notable expansion of their commercial partnership. The collaboration aims to accelerate the development and deployment of integrated quantum and generative AI solutions in D-Wave’s Leap quantum cloud platform (https://ibn.fm/jcUJp).

The expanded agreement will utilize Zapata’s proprietary universal generative AI software for rapid development and build on D-Wave’s Leap real-time quantum cloud service to support quantum, hybrid quantum, and classical AI solutions. The partnership’s development efforts will target more efficient and energy-saving model training, higher-performing models, and the combined use of generative AI and quantum optimization.

The broadened collaboration is taking place at a time when quantum computing is showing its potential to enhance the accuracy and efficiency of AI model training. By utilizing AI’s predictive capabilities, quantum computing can optimize business processes more effectively. This technology has the potential to enhance AI for specific enterprise applications, promoting sustainability, reducing costs, and improving operational efficiency. Quantum computing could advance AI development for complex, large-scale computational models, deep learning, natural language processing, and computer vision, all while minimizing energy consumption.

Dr. Alan Baratz, CEO of D-Wave, said the strategic relationship with Zapata AI brings the company a step closer to delivering the transformative combined power of universal generative AI and quantum computing in a single cloud platform. “Zapata AI has been pioneering quantum-based generative modeling for over five years, well before generative AI stole headlines and became a mainstream enterprise priority,” Baratz said. “We are excited to deepen our partnership with Zapata and leverage their industry-leading algorithmic capabilities and scientific expertise to bring a quantum-enabled generative AI platform to market.”

D-Wave also recently hosted B.C. Minister of State for Trade, Jagrup Brar, and B.C. Parliamentary Secretary for Labour, Janet Routledge, at its Burnaby-based Quantum Engineering Center of Excellence. The officials toured the facility to gain insights into D-Wave’s advancements in quantum computing and its global efforts to promote quantum adoption (https://ibn.fm/DRo9N).

During the visit, D-Wave and the Quantum Algorithm Institute (“QAI”) announced an expanded training program to provide Canadian students and researchers with access to the Leap quantum cloud service in an effort to develop a quantum-ready workforce. This program has seen solid traction, with nearly 5000 problems submitted by students so far.

D-Wave shared key company advancements with the government officials, including its new hybrid quantum solver, enhanced qubit architecture, and real-world applications that address e-commerce, sustainability, and public sector challenges. The officials acknowledged D-Wave’s role in driving innovation, creating jobs, and its commitment to workforce development through its partnership with QAI.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

The FinovateFall 2024 event, held from September 9-11, 2024, at the Marriott Marquis Times Square, New York, offers the premiere interactive business platform, for industry experts, startups, and unicorns, to stage demos and showcase innovative ideas.

FinovateFall New York will witness 2,000+ attendees interacting with peers and industry leaders on the event floor, with over 1,000 bank and financial institution representatives, and with 1,400+ attendees being top executives, directors, and VPs. Directly connected to the exhibition floor, the event features 60+ demos from companies aspiring for business opportunities.

The agenda of the FinovateFall includes general sessions, demos, exhibit hall networking, keynote addresses, and executive briefings on pivotal topics regarding financial services and technology. Drinks and dinner breaks offer attendees a great opportunity to connect directly with industry stalwarts and develop strong networking ties. The agenda is designed for attendees to gain expert insights and help them smoothly navigate their financial and fintech businesses in the future.

The event will feature an out-of-the-box keynote address by Ken Hughes, A Consumer Behaviouralist and King of Customer Experience, in the Session: The Blue Dot Consumer. Around 120 eminent industry dignitaries will preside over the keynote speaker sessions. These industry leaders will share their expertise and discuss the latest topics, including AI and wealth management, regulatory services, competing in the digital world, and third-party risk management, to name a few.

Investors can discover fresh ideas and new investment avenues among these demos and exhibits. There will be over countless meetings where investors can meet companies and entrepreneurs on a one-to-one basis. Fintech companies with sustainability and inclusion ideas can also avail the Fintech scholarship program.

To know more, please visit https://ibn.fm/5x9bn

• The report explores the growth, competition, and consumer trends, for lesser known cannabinoids
• The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion
• As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve

With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits, there is a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth.

BayMedica, a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), specializes in rare cannabinoids, and has published a report on the expansion of the minor cannabinoid market in 2023. Link to a full copy of the report can be found at https://ibn.fm/Jowk5.

The report, based on data from Headset, the largest industry dataset, explores the growth, competition, and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal (https://ibn.fm/74fQB).

The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion. This growth is attributed to innovative developments in minor cannabinoid products. Among edible products, gummies demonstrated robust sales, while minor cannabinoid-infused edibles experienced an impressive 47% year-over-year growth, totaling $391 million in sales.

Despite a decrease in the average price of edible items from $14.29 to $12.54, the strong consumer demand and reduced production costs have made minor cannabinoids a strategic focus for brands aiming to secure a competitive position in the industry.

Minor cannabinoids, although less prominent than THC and CBD, are gaining attention for their distinctive properties and potential health benefits. These compounds, found in smaller quantities in cannabis plants, are transforming the cannabinoid landscape. Key minor cannabinoids include:

• Cannabichromene (“CBC”): Known for enhancing the body’s natural endocannabinoid, anandamide, by prolonging its presence in the bloodstream
• Tetrahydrocannabivarin (“THCV”): Non-psychoactive, it may suppress appetite and enhance focus and energy
• Cannabidivarin (“CBDV”): Similar to CBD, it potentially supports brain, immune, and gut health
• Cannabinol (“CBN”): Mildly psychoactive, known for its sedative and antibacterial properties, beneficial for insomnia and pain relief

The endocannabinoid system (“ECS”), discovered in the late 1980s, plays a crucial role in regulating various body functions. Every cell type has cannabinoid receptors that interact with over 140 known cannabinoids. The ECS’s therapeutic potential spans numerous diseases, though extracting minor cannabinoids is challenging due to their low quantities and the high cost of separation. BayMedica’s advancements in biosynthesis and synthetic chemistry now allow for commercial-scale production, opening new therapeutic avenues.

In 2023, nearly half of the top 50 selling edibles contained minor cannabinoids, reflecting a significant market trend. Leading brands are innovating with formulations that appeal to a diverse consumer base, allowing them to command premium pricing for minor cannabinoid products. These products have a 6.3% higher average price and a 73% higher average EQ (Equivalent) price compared to THC-only products, indicating a strong consumer willingness to pay for added benefits. The entourage effect theory suggests that combining minor cannabinoids with major cannabinoids like THC and CBD enhances medicinal benefits, such as pain relief.

Commercial adoption of minor cannabinoids in edibles provides insights into consumer preferences. CBN has emerged as a leader in sales, likely due to its sedative effects. CBG, while currently strong, may see a future decline as other minor cannabinoids gain traction. CBC and THCV have shown significant sales growth in 2023, driven by research into their potential benefits and increased production efficiency.

As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the cannabis product landscape is set to evolve. Brands must align with these changing needs, emphasizing minor cannabinoids for holistic well-being. BayMedica remains committed to scaling operations and expanding product offerings to meet the rising demand for high-quality cannabinoids, supporting a broad and growing customer base.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
• CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
• ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and utilization, driving critical cellular reactions that promote neuroprotection and remyelination, thereby enhancing neuronal and glial resilience to disease-related stressors.

In a recent Xtalks podcast, Clene discussed the significant developments of CNM-Au8 and its unique technology. CNM-Au8’s mechanism of action involves the conversion of critical energetic metabolites within living cells to produce ATP, the essential energy currency for cellular functions. The gold nanocrystals attract a coating of apolipoproteins from human plasma, facilitating their passage through the blood-brain barrier and into the brain, where they can protect neurons from death and repair damaged neurons by catalyzing energy production (https://ibn.fm/Gvb5o).

CNM-Au8 is being evaluated in multiple clinical trials, including the prestigious Harvard/MGH HEALEY ALS Platform Trial, which targets patients with mid-to-late stage ALS. The drug has also completed the RESCUE-ALS proof-of-concept clinical trial for early symptomatic ALS, and the REPAIR trials, showing promising changes in brain energy metabolites with CNM-Au8 administration. Additionally, CNM-Au8 has completed a clinical trial, VISIONARY-MS, for treating visual pathway deficits in chronic optic neuropathy, demonstrating its potential for remyelination in stable relapsing MS.

With more than 650 estimated years of collective exposure across ALS, MS, and PD participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs, CNM-Au8 has shown a robust safety profile without any observed safety signals. The drug is designed to be used in combination with other agents and has no known drug-drug interactions, making it a versatile option for patients.

ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide. Clene estimates that global ALS treatment sales will exceed $1 billion annually in the coming years, underscoring the urgent need for viable treatment options.

Founded in 2013 and based in Salt Lake City, Utah, Clene Inc. is at the forefront of developing innovative treatments for neurodegenerative diseases. With research and development, as well as manufacturing operations in Maryland, Clene is committed to transforming the treatment landscape for ALS, MS, PD, and other debilitating conditions through its groundbreaking nanotherapeutic platform.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• The U.S. snack market is predicted to grow to $169.6 billion by 2027
• 93% of adults regularly snack at night combining for over 1 billion bedtime snacks consumed every week.  Unfortunately, the most popular choices are both unhealthy and sleep-disruptive
• Nightfood, with their newly launched sleep-friendly cookie line, is poised to lead the burgeoning sleep-friendly nighttime snack category
• Earlier this month, Nightfood Holdings signed a letter of intent to acquire CarryoutSupplies.com, an established restaurant and foodservice packaging provider that is on the upswing after business suffered greatly during the pandemic

The U.S. snack market is experiencing robust growth, fueled by evolving consumer preferences that prioritize wellness and functionality.  According to Eurometer International, the U.S. snack market will reach $169.6 billion by 2027.  With never-ending social media and video streaming on demand, Americans are staying up later at night and snacking more than ever.

The late-night snacking occasion is a massive and untapped niche within the snack industry. A 2023 Sleep Foundation survey revealed that 93% of American adults snack between dinner and bed each week, with the average adult snacking before bed 3.9 nights per week. The result is over 1 billion nighttime snacks consumed by American adults every week, and a consumer spend estimated at well over $60 billion annually.

A recent survey by Kellanova (NYSE: K), formerly Kellogg Company, revealed that cookies, ice cream, and chips top the list of nighttime snacks. These are not only generally unhealthy, but their sugar, fat, and caloric content can also directly impair sleep quality. The immense consumer spend on snacks consumed before bed understandably has the attention of global snack giants such as Kellanova (NYSE: K), Nestle (OTC: NSRGY), Mondelez (NASDAQ: MDLZ), Post Holdings (NYSE: POST), and others.

Nightfood Holdings (OTCQB: NGTF) is pioneering the concept of sleep-friendly nighttime snacks and is largely alone in targeting an exploding consumer use case.  Nightfood is positioned to be the leader in the sleep-friendly nighttime snack category, which the brand is pioneering.  And now the company has made a move that signals new things to come which must not be overlooked.

In addition to its core sleep-friendly snack business, Nightfood has strategically focused on expanding its reach within the broader foodservice ecosystem. In July, the company announced a letter of intent to acquire CarryOutSupplies.com, a wholesale provider of packaging and supplies and to the foodservice industry. This move reflects NGTF’s ambition to become a comprehensive player in the sector.

Nightfood Holdings sees a golden opportunity in acquiring CarryOutSupplies.com right now. CarryOut is a well-established restaurant packaging distributor which has served a client base of over 7,000 foodservice and restaurant locations over the years.  The company is now bouncing back after COVID challenges.

CarryOut’s eco-friendly packaging solutions align perfectly with Nightfood’s focus on innovation and cater to a growing market trend. The reemerging company recorded sales of just over $2 million in calendar 2023, a positive sign, yet still a fraction of pre-COVID revenue. Nightfood believes CarryOut can not only regain pre-pandemic success but also surpass it, especially by targeting up and coming growth foodservice chains with CarryOut’s unique and eco-friendly packaging options.

A bolt-on of $2 million in sales certainly will look good in Nightfood’s books. The company launched robots-as-a-service (“RaaS”) model through its subsidiary, Future Hospitality Ventures Holdings, addressing labor cost and labor shortage in the hospitality industry.

As consumer preferences evolve and the demand for sleep-friendly options grows, Nightfood is well-positioned to capture a meaningful segment of the expanding late-night snacking market. By addressing the unmet needs of consumers with sleep-friendly snacks, Nightfood is not only shaping the future of the nighttime snacking category but also establishing itself as a major player in the broader landscape.

For more information, visit the company’s website at https://ir.nightfood.com/.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF